Articles tagged "Kidney transplantation"

2018 American Transplant Congress
The Effect of Perioperative Antiplatelet/Anticoagulant Therapy on the Incidence of Early Postoperative Thromboembolic Complications and Bleeding in Kidney Transplantation – A Dual Center Retrospective Cohort Study of 2000 Kidney Transplant Recipients
T. van den Berg,¹ R. Minnee,² G. Nieuwenhuijs-Moeke,³ S. Bakker,⁴ R. Pol.¹
¹Department of Surgery, University Medical Center Groningen (UMCG), Groningen, Netherlands; ²Department of Surgery, Erasmus Medical Center, Rotterdam, Netherlands; ³Department of Anesthesiology, UMCG, Groningen, Netherlands; ⁴Department of Internal Medicine-Nephrology, UMCG, Groningen, Netherlands.
Thromboembolic complications (TECs) are dreaded complications after kidney transplantation (KTx). Consequences are severe and can result in delayed graft function or even graft loss. Perioperative…
2018 American Transplant Congress
CFZ533, a New Anti-CD40 mAB Demonstrates Comparable Efficacy and Better Renal Function versus Tacrolimus in De-Novo CNI-Free Kidney Transplantation
B. Nashan,¹ H. Tedesco,¹ M. van den Hoogen,¹ S. Berger,¹ D. Cibrik,¹ S. Mulgaonkar,¹ D. Leeser,¹ R. Alloway,¹ A. Patel,¹ J. Pratschke,¹ C. Sommerer,¹ A. Wiseman,¹ A. van Zuilen,¹ U. Laessing,² J. Rush,² B. Haraldsson,² O. Witzke.¹
¹CFZ533 Study Group, Basel, Switzerland; ²Novartis Pharma, Basel, Switzerland.
Purpose: To assess the potential of CFZ533 as primary immunosuppressant in a calcineurin(CNI)-free regimen in de novo kidney transplant (KTx) patients(pts).Method: CFZ533 is a new,…
2018 American Transplant Congress
Development of Denovo DSA after One Year Post Kidney Transplant and Clinical Outcomes in Patient on Steroid Free Immunosupression
A. Sharfuddin, M. Yaqub, D. Mishler, W. Goggins, T. Taber, O. Adebiyi.
Division of Renal Disease and Hypertension, Indiana University Health Transplant Program, Indianapolis, IN.
Background: Development of Denovo donor specific antibodies (DnDSA) has been associated with poor allograft outcomes in few studies. However, there is scarcity of data evaluating…
2018 American Transplant Congress
IL-6 Inhibition with Tocilizumab to Promote Tregs and Control Renal Graft Inflammation: A Prospective Randomized Controlled Trial
S. Chandran, J. Leung, Z. Laszik, Q. Tang, C. Hu, M. Sarwal, F. Vincenti.
UCSF, San Francisco.
Background: IL-6, a proinflammatory cytokine & key regulator of Treg/Th17, is strongly associated with renal graft rejection. In theory, IL-6 blockade with tocilizumab (TCZ), a…
2018 American Transplant Congress
All DQ DSA May Not Be Equal: Comparing Outcomes between De Novo DQ DSA Specificities
M. Everly,¹ K. Briley,² A. Nguyen,¹ V. Jucaud,¹ A. Maldonado,³ C. Haisch,² P. Bolin,² S. Kendrick,⁴ H. Jones,⁴ K. McLawhorn,⁴ D. Leeser,² L. Rebellato.²
¹Terasaki Research Institute, Los Angeles; ²East Carolina University, Greenville, NC; ³Vidant Medical Center, Greenville, NC; ⁴Eastern Nephrology Associates, Greenville, NC.
It is not known if development of de novo DSA (dnDSA) to different HLA-DQ mismatches (serological) are associated with equal risk to a patient's allograft…
2018 American Transplant Congress
Hospital Readmissions Following ABO-Incompatible Live Donor Kidney Transplantation: A National Study
B. Orandi,¹ X. Luo,² S. Bae,² E. King,² J. Garonzik-Wang,² D. Segev.²
¹UCSF, San Francisco; ²Hopkins, Baltimore.
30% of kidney transplant recipients are readmitted in the first month post-transplant. ABO-incompatible (ABO-I) recipients constitute a unique subpopulation that might be at higher readmission…
2018 American Transplant Congress
Serial Monitoring of Resolution of Sub-Clinical Acute Rejection (subAR) in Kidney Transplant Recipients (KTR) Using a Gene Expression Profile (GEP)
L. Zhao,¹ B. Armstrong,² J. Friedewald,¹ T. Whisenant,³ S. Kurian,³ R. Heilman,⁴ E. Poggio,⁵ C. Marsh,³ P. Baliga,⁶ N. Bridges,⁷ J. Odim,⁷ M. Brown,⁷ D. Ikle,² J. Charette,¹ S. Brietigam,¹ N. Sustento-Reodica,¹ M. Kandpal,¹ D. Salomon,³ M. Abecassis.¹
¹Northwestern, Chicago; ²Rho, Chapel Hill; ³Scripps, La Jolla; ⁴Mayo AZ, Scottsdale; ⁵Cleveland Clinic, Cleveland; ⁶MUSC, Charleston; ⁷NIAID, Bethesda.
BACKGROUNDSubAR can currently only be detected using surveillance biopsies (SBx) and is associated with poor long-term graft outcomes. Response to treatment is difficult to assess.…
2018 American Transplant Congress
Circulating Wnt Pathway Factors Are Non-Invasive Biomarkers of Transplant Vascular Injury
M. Seifert,¹ A. Malone,² L. Boohaker,¹ J. Gaut,² S. Jain,² D. Brennan,^2,3 R. Mannon.¹
¹UAB School of Medicine, Birmingham; ²Washington University, St. Louis; ³Johns Hopkins University, Baltimore.
Purpose: Transplant vascular injury (TVI) is a major cause of renal allograft failure and is resistant to treatment. Non-invasive pathogenic biomarkers of TVI would provide…
2018 American Transplant Congress
Molecular Monitoring for Kidney Allograft Injury Following HLA Incompatible Transplantation
A. Jackson,¹ B. Iglehart,¹ S. Bagnasco,³ N. Desai.²
¹Medicine, Johns Hopkins University, Baltimore, MD; ²Surgery, Johns Hopkins University, Baltimore, MD; ³Pathology, Johns Hopkins University, Baltimore, MD.
Elevated donor derived cell free DNA (ddcfDNA) has been shown to correlate with allograft rejection following heart, lung, and kidney transplantation. We investigated whether sequential…
2018 American Transplant Congress
ABO-Incompatibility Lower Incidence of DSA-Induced Antibody-Mediated Rejection
D. Lee,¹ B. Kim,¹ J. KIm,¹ I. KIm,¹ M. Jeon.¹
¹Nephrology, Medicine, Maryknoll General Hospital, Busan, Republic of Korea; ²Laboratory Medicine, Maryknoll General Hospital, Busan, Republic of Korea; ³Surgery, Maryknoll General Hospital, Busan, Republic of Korea; ⁴Urology, Maryknoll General Hospital, Busan, Republic of Korea; ⁵Pathology, Maryknoll General Hospital, Busan, Republic of Korea.
Introduction:Donor-specific anti-HLA antibody (DSA) and Anti-ABO antibody are major barriers for successful kidney transplantation. Limited data are available about the existences of both DSA and…